PMV Pharmaceuticals
PMVP
99 hedge funds and large institutions have $1.15B invested in PMV Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 30 reducing their positions, and 19 closing their positions.
30% more call options, than puts
Call options by funds: $15.6M | Put options by funds: $12M
16.95% more ownership
Funds ownership: 104.61% → 121.56% (+17%)
13% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 30
5% more capital invested
Capital invested by funds: $1.1B → $1.15B (+$53.8M)
6% less funds holding
Funds holding: 105 → 99 (-6)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
21% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$71.7M |
| 2 |
CAC
Cowen and Company
New York
|
+$22.3M |
| 3 |
RI
RTW Investments
New York
|
+$15.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$15.7M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$13.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$17.3M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$12.6M |
| 3 |
DM
Deerfield Management
New York
|
-$9.2M |
| 4 |
O
OrbiMed
New York
|
-$8.38M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.4M |
PMVP Hedge Fund Activity: Q1 2022 in Review
99 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q1 2022, worth a combined $1.15B — up 4.9% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PMVP and 15 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 34 added.
The largest buyer was Morgan Stanley, adding an estimated $71.7M. The largest seller was Victory Capital Management, cutting an estimated $17.3M.
- 99 institutional investors held PMV Pharmaceuticals (PMVP) as of Q1 2022, down from 105 in Q4 2021.
- Funds reported $1.15B of PMV Pharmaceuticals stock for Q1 2022, up 4.9% quarter-over-quarter.
- 15 funds opened new PMV Pharmaceuticals positions in Q1 2022 and 19 closed out, a net change of -4 holders.
- The largest PMV Pharmaceuticals buyer in Q1 2022 was Morgan Stanley, an estimated $71.7M added.
- The largest PMV Pharmaceuticals seller in Q1 2022 was Victory Capital Management, an estimated $17.3M sold.
Based on aggregated 13F filings for Q1 2022.